In this issue:
Outcomes of patients with indolent lymphoma
Nivolumab + brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma
The phase 2 CAPTIVATE study
Venetoclax plus obinutuzumab improves quality of life and geriatric impairments
Mosunetuzumab monotherapy for R/R B-cell lymphoma
Risk of male breast cancer after Hodgkin lymphoma
Vitamin D3 supplementation with imatinib for chronic myeloid leukaemia
Acalabrutinib plus danvatirsen (AZD9150) in R/R B-cell lymphoma
Final analysis of the CLL2-GIVe trial
Lisocabtagene maraleucel in chronic lymphocytic leukaemia
Please login below to download this issue (PDF)